Potent Cyclic Peptide Inhibitors of FXIIa Discovered by mRNA Display with Genetic Code Reprogramming
Daniel Ford, Nisharnthi M. Duggan, Sarah E. Fry, Jorge Ripoll‐Rozada, Stijn M. Agten, Wenyu Liu, Leo Corcilius, Tilman M. Hackeng, René van Oerle, Henri M.H. Spronk, Anneliese S. Ashhurst, Vishnu Mini Sasi, Joe A. Kaczmarski, Colin J. Jackson, Pedro José Barbosa Pereira, Toby Passioura, Hiroaki Suga, Richard J. Payne
Abstract
The contact system comprises a series of serine proteases that mediate procoagulant and proinflammatory activities via the intrinsic pathway of coagulation and the kallikrein–kinin system, respectively. Inhibition of Factor XIIa (FXIIa), an initiator of the contact system, has been demonstrated to lead to thrombo-protection and anti-inflammatory effects in animal models and serves as a potentially safer target for the development of antithrombotics. Herein, we describe the use of the Randomised Nonstandard Peptide Integrated Discovery (RaPID) mRNA display technology to identify a series of potent and selective cyclic peptide inhibitors of FXIIa. Cyclic peptides were evaluated in vitro, and three lead compounds exhibited significant prolongation of aPTT, a reduction in thrombin generation, and an inhibition of bradykinin formation. We also describe our efforts to identify the critical residues for binding FXIIa through alanine scanning, analogue generation, and via in silico methods to predict the binding mode of our lead cyclic peptide inhibitors.